Inter-rater reliability, as measured by the ICC and
QWK, was substantial.
IV Iron dextran 100 mg is administered over the course of 5 min
QWK for 10 doses or as a 1-g infusion administered during the course of several hours.
Patient 12 was also treated with IVIG 1 mg/kg/day for 2 d, and rituximab 375 mg m-2
QWK (only 2 doses were available due to off-label administration) was administered in an effort to discontinue CsA, but CsA dependence persisted for 13 months, after which time it was discontinued.
Eculizumab (Soliris, Alexion Pharmaceuticals[R]) therapy began in November 2008 with an induction dose of 600 mg
QWK for 4 weeks, and then 900 mg (single dose) 7 days later, followed by a maintenance dose of 900 mg (single dose) after 1 month.